INmune Bio : Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's disease - Form 8-K
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's disease INmune Bio Plans to Enroll 201 Patients... | April 13, 2022